NPT-088
/ Proclara Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 08, 2019
Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer's Disease.
(PubMed, J Prev Alzheimers Dis)
- "At endpoint NPT088 was generally safe and well-tolerated with the most prominent finding being infusion reactions in a minority of patients. No effect of NPT088 on brain plaques, tau aggregates or Alzheimer's disease symptoms was observed."
Clinical • Journal • Alzheimer's Disease • CNS Disorders
August 15, 2019
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease
(clinicaltrials.gov)
- P1; N=83; Completed; Sponsor: Proclara Biosciences, Inc.; Active, not recruiting ➔ Completed
Clinical • Trial completion
1 to 2
Of
2
Go to page
1